Fig. 8.
ImmTAB-inhA redirects T cells to kill Mtb-infected primary human cells. (A) Quantification of inhA mRNA in Mtb-infected PBMC by quantitative reverse transcription PCR plotting the average transcript number per 100 ng RNA from three PBMC donors. Mtb H37Rv cultured in broth and noninfected PBMC were included as positive and negative controls, respectively. (B) ImmTAB-inhA-mediated cell death of Mtb-infected primary cells in coculture with autologous healthy donor PBMC and 10 nM ImmTAB-inhA was determined by measuring luminescence using the ToxiLight assay. Controls included uninfected PBMC with and without ImmTAB-inhA, and Mtb-infected PBMC cocultured with or without a CD3 nonbinding version of ImmTAB-inhA (anti-CD3mut ImmTAB-inhA). Data represent mean ± SD of triplicates and are representative of three healthy donor PBMC assayed. ****p < 0.01.